Revenue : 000,000 M USD
Finance : 000,000 M USD
Earning Cap : 000,000 M USD
Invest : 000,000 M USD
R & D : 0000 People
Growth : 00% AGR



General Introduction Xiamen Aide Biomedical Technology Co., Ltd. was founded by Professor Zheng Limou in 2008 after returning to China. It focuses on the field of molecular diagnosis in tumor precision medicine and technological innovation that benefits the people. It is committed to providing patients with compliant and high-quality diagnostic products and services, allowing them to truly benefit from precision medicine. The company has qualifications such as National Enterprise Technology Center, Postdoctoral Research Workstation, Gene Testing Technology Application Demonstration Center of the National Development and Reform Commission, National High tech Enterprise, and Fujian Cancer High throughput Sequencing Engineering Research Center. The GMP standard factory has been certified by the National Medical Products Administration (NMPA) and the European Union ISO13485 certification; The company has core technologies such as ADx ARMS, Super ARMS, ddCapture, ADx HANDLE, etc. The core technologies have been authorized by China, the United States, the European Union, and Japan, and have won the second prize of the National Science and Technology Progress Award and the silver medal of the Chinese Patent Award; The company's products cover various major cancer types with precise medical conditions, and there are still no competitors for multiple products. In addition to large-scale application in domestic tertiary hospitals, some products have been approved for marketing in Japan and South Korea and have entered local medical insurance, setting a precedent for overseas approval of tumor accompanied diagnosis in China. In addition, the company has Xiamen Aide Medical Laboratory and Shanghai Xiawei Medical Laboratory, which have a medical institution practice license and are certified by the American Society of Pathology (CAP). They specialize in third-party clinical examination services. At present, customers from dozens of countries and regions around the world have chosen Ed products and services, benefiting hundreds of thousands of cancer patients every year, effectively avoiding the misuse and abuse of cancer drugs. The company aims at the source of industry innovation and empowers the clinical use of original research drugs through diagnosis. It is a strategic partner in the development of tumor drugs for top domestic and foreign pharmaceutical companies such as AstraZeneca, Johnson&Johnson, Anjin, Lilly, Merck, Weicai, Hengrui, and Baekje, jointly building the future of precise cancer medicine.
Headquarter Xiamen
Establish Date 2/21/2008
Listed Code 300685.SZ
Listed Date 8/2/2017
Chairman LI MOU ZHENG.

Buy Premium Now

$15/month billed now

View the full stack of insights immediately

Or 7 Days Free Charge for Trial

See feature available in the Trial and Premium

See our Solution and Servicetrial.solutionservice.trial

See our Uniquness and Value deliveringtrial.solutionservice.trial